Compare · EW vs JMG
EW vs JMG
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and JM Group Limited (JMG): market cap, price performance, sector, and recent activity on the wire.
Summary
- EW operates in Health Care, while JMG operates in Consumer Discretionary - the two are in different parts of the market.
- EW carries a market cap of $50.78B.
- Over the past year, EW is up 15.0% and JMG is up 20.9% - JMG leads by 5.9 points.
- EW has hit the wire 5 times in the past 4 weeks while JMG has been quiet.
- EW has more recent analyst coverage (25 ratings vs 0 for JMG).
- Company
- Edwards Lifesciences Corporation
- JM Group Limited
- Price
- $86.61-1.66%
- $6.76-5.72%
- Market cap
- $50.78B
- -
- 1M return
- -1.84%
- +0.00%
- 1Y return
- +15.02%
- +20.93%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- AMEX
- IPO
- 2025
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 0
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest EW
- SEC Form 4 filed by Edwards Lifesciences Corporation
- Barclays initiated coverage on Edwards Lifesciences with a new price target
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCT
- Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision
Latest JMG
- SEC Form 25-NSE filed by JM Group Limited
- SEC Form 6-K filed by JM Group Limited
- JM Group Limited Announces Receipt of NYSE American Notice of Delisting
- SEC Form 6-K filed by JM Group Limited
- JM Group Limited Provides Further Update Regarding Trading Halt of its Securities
- JM Group Limited Announces Filing of Annual Report on Form 20-F Fiscal Year 2025
- SEC Form 3 filed by new insider Li Sze Wai
- SEC Form 3 filed by new insider Ting Chun Kwok Stanley
- SEC Form 3 filed by new insider Zheng Kin
- SEC Form 3 filed by new insider Ting Rita